Empagliflozin surpasses glimepiride as metformin add-on
NEW ORLEANS – When used as an add-on therapy to metformin in patients with type 2 diabetes mellitus, empagliflozin has sustained safety and efficacy in reducing in hemoglobin A1c...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news
More News: Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Fortamet | Glimepiride | Jardiance | Metformin